
Isomorphic Labs Raises $5B: What the Series C Signals
Isomorphic Labs raised a $5 billion Series C co-led by Greenoaks and Sequoia, with Alphabet investing again. Here is what it signals for AI drug discovery.
Isomorphic Labs just raised $5 billion, and even in a year of giant AI checks, that number stands out. The AI drug discovery company founded by Demis Hassabis announced its Series C on November 17, 2026. For investors, it is one of the clearest signals yet of where private capital thinks AI's next big payoff will come from: medicine.
- Round size: $5 billion Series C
- Co-leads: Greenoaks and Sequoia Capital, alongside Andreessen Horowitz and other new investors
- Returning backers: Alphabet, plus Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund
- Context: Isomorphic's previous raise was a $2.1 billion Series B in May, CNBC reports
What Did Isomorphic Labs Announce?
The company says the round was co-led by Greenoaks and Sequoia Capital, joined by Andreessen Horowitz and several other new investors. Alphabet made what Isomorphic calls a continued significant investment, and every existing investor took part.
Isomorphic designs and develops new medicines with AI. It is scaling a proprietary drug design engine it calls IsoDDE, along with a pipeline of therapeutic candidates designed with that engine. In a statement carried by CNBC, Hassabis said the funding will go toward building foundational biology models, deepening the company's understanding of disease, and moving its first therapeutic programs toward clinical trials.
The announcement did not include a valuation.
Who Is Behind Isomorphic Labs?
Isomorphic spun out of Google DeepMind in 2021, and Hassabis has been its chief executive since then. CNBC notes the round comes about three and a half months after he stepped back as DeepMind's CEO. The company grew out of the same research tradition that produced DeepMind's biology models. We looked at a recent example of that work in our piece on AlphaGenome 2 and cell-level DNA predictions.
Why Does a $5 Billion Round Matter for Investors?
Here is the way I think about it. A funding round this size is not just a headline. It is a read on where sophisticated money sees durable value.
It confirms a sector trend. Drug discovery startups have raised $23.2 billion in 2026, a record, according to Dealroom data cited by CNBC. Isomorphic's round alone is a large slice of that.
It shows patience. Drug development takes years. Investors writing checks this large are funding clinical trials, not a quick product launch.
It shows breadth. Growth funds, venture firms, sovereign investors and a public parent company all showed up in the same round. That mix suggests conviction across very different types of capital.
It is a crowded field in a good way. CNBC points out that Anthropic launched an AI drug discovery program in June and OpenAI partnered with Novo Nordisk in April. When the biggest AI labs and the biggest funds point the same direction, it is worth paying attention.
Can You Invest in Isomorphic Labs?
Not directly. Isomorphic is a private company, so its shares do not trade on a public exchange. A few things are still useful to know:
- Alphabet is the public link. Alphabet invested again in this round, and its venture arms GV and CapitalG are also on the list. Isomorphic is a small part of a very large company, so it is not a pure play
- Private rounds are not public prices. A funding round tells you what private investors paid under private terms. It is not the same as a stock quote
- The path to public markets is open. This year has shown that large AI companies can and do list, as we covered in our explainer on the Anthropic IPO price range. Isomorphic has not announced any plans to go public
As always, this is context for understanding the market, not a recommendation to buy or sell anything.
The Takeaway
The big-picture story is a hopeful one. Billions of dollars are flowing toward using AI to design medicines faster, and the next milestones to watch are clinical ones: which programs enter trials and what the results show. That is the kind of AI news that could matter well beyond a portfolio. There is more market context in our stock trading coverage.
Sources: Isomorphic Labs — November 17, 2026; CNBC — November 17, 2026.
More Stock Trading Stories

JPMorgan AI Agents: What the Hyundai Card FX Test Proved
JPMorgan and Hyundai Card tested AI agents on simulated FX trades over Kinexys. A multi-agent phase is targeted for the first half of 2027. Here's why.

Cerebras Q3 Earnings: 265% Cloud Growth and a Tripling Plan
Cerebras posted record Q3 revenue of $210.8M, 265% cloud growth and a $310M-$330M Q4 outlook, then said it expects to triple revenue in 2027.

Intel vs AMD CPU Market Share: What Q3 2026 Data Shows
Intel regained overall x86 CPU market share in Q3 2026 per Mercury Research, while AMD set server and mobile records. What investors should watch next.
